Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma

BACKGROUND: Precision medicine calls for an early indicator of treatment efficiency. Circulating tumor DNA (ctDNA) is a promising marker in this setting. Our prospective study explored the association between disease development and change of ctDNA during first line chemotherapy in patients with RAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, C. B., Hansen, T. F., Andersen, R. F., Lindebjerg, J., Jensen, L. H., Jakobsen, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848434/
https://www.ncbi.nlm.nih.gov/pubmed/29530101
http://dx.doi.org/10.1186/s13046-018-0723-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848434/
https://www.ncbi.nlm.nih.gov/pubmed/29530101
http://dx.doi.org/10.1186/s13046-018-0723-5

Ejemplares similares